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Abstract The in vitro antibacterial activity of a series of
phosphanegold(I) dithiocarbamates, R3PAu[S2CN
(iPr)CH2CH2OH] where R = Ph (2), Cy (3) and Et (4), against
25 strains of Gram-positive and Gram-negative bacteria were
determined through the disk diffusion method, the determina-
tion of minimum inhibitory concentration (MIC) and mini-
mum bactericidal concentration (MBC) and by time-kill assay.
Compounds 2 and 3 have been shown to be specifically active
against the tested Gram-positive bacteria, with MIC values
ranging from 7.81 to 125 μg/ml. Compound 4 has a broad-
spectrum activity against 24 strains of Gram-positive and
Gram-negative bacteria, with MIC values ranging from 0.98
to 1,000 μg/ml. Noteworthy was that 4, with a very low MIC
value of 0.98 μg/ml, is particularly effective against
methicillin-resistant Staphylococcus aureus (MRSA) and
Bacillus sp., as effective as the standard antibiotic ciproflox-
acin. In time-kill studies, the bacteriostatic and bactericidal
activities of the tested compounds towards susceptible strains
were similar to their characteristics determined by MBC/MIC
ratios. In the time-kill assay, 2 and 3 showed only bactericidal
activity towards the susceptible strains tested, whereas 4 re-
vealed varying degrees of bactericidal and bacteriostatic ac-
tivities, results indicating different antibacterial mechanisms
are involved.
Keywords Gold(I) compounds . Dithiocarbamates .
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Introduction
The emergence of resistance in pathogenic bacteria to multiple
antibacterial agents has become a significant public health
issue as there are fewer, or even sometimes no, effective
antibiotic treatments available for these infectious diseases
[1]; also see recent commentaries on this issue [2, 3]. Apart
from patients themselves, the threat of multidrug-resistant
bacteria posed towards frontline health workers has also in-
creased [4]. Due to their natural behaviour of rapid life cycle,
fast reproduction and the ability to exchange genetic informa-
tion with other strains of bacteria, the chances of bacteria to
develop resistance to currently available antibiotics are fairly
high [5]. Hence, over and above improving health care hy-
giene, there is a clear imperative to develop novel antimicro-
bial agents needed to meet the challenges posed by the rapid
emergence of multidrug-resistant pathogens. As a case in
point, over time, the original Gram-positive bacterium Staph-
ylococcus aureus developed resistance towards a series of
first-line, second-line and even third-line antibiotics [6] to
evolve into methicillin-resistant S. aureus (MRSA). Now, as
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MRSA is able to resist the beta-lactam group of antibiotics,
the treatment of this highly prevalent pathogen has become an
urgent challenge. As a contribution to the development of new
and effective antibacterial agents, herein, synthetic gold com-
pounds derived from phosphanegold(I) dithiocarbamate
(Fig. 1) are demonstrated to exhibit convincing effects against
a broad range of pathogens, including the particularly virulent
bacterium, MRSA.
Since earliest civilization, gold and its compounds have
been utilized by medical practitioners to treat various health-
related problems, and amongst these are bacterial infections
[7–10]. Despite this, antibacterial studies on gold compounds
are still relatively limited [10–15] and more often than not
focussing on gold(I) rather on gold(III) compounds. The pri-
mary focus of these studies is usually upon the inherent
interest in the chemistry and consequently the accompanying
antimicrobial work is often limited to the measurement of
minimum inhibitory concentration (MIC) and sometimes min-
imum bactericidal concentration (MBC). One limitation of
these studies is the inability of the method(s) to determine
the kinetics of interaction between the putative antibacterial
agents and the bacteria under investigation. In the present
study, the MIC and MBC scores of some phosphanegold(I)
dithiocarbamates (Fig. 1) against a wide range of Gram-
positive and Gram-negative bacteria are determined. This is
augmented by an assessment of the killing kinetics determined
by a time-kill assay, therefore enhancing the understanding of
the pharmaco-dynamic relationships between the
phosphanegold(I) dithiocarbamates and their effects on
bacteria.
Reflecting the increasing interest in the antimicrobial ac-
tivity of gold compounds, very recently, a comprehensive
review of the developments in this field appeared [16]. While
studies have been reported on phosphanegold(I) mono-
functional thiolate compounds, none have yet appeared for
bi-functional dithiolate analogues, such as dithiocarbamate.
This is perhaps a little surprising owing to the substantial and
ongoing efforts investigating the anti-tumour potential of gold
dithiocarbamates. Thus, directly related to the compounds
shown in Fig. 1, i.e. phosphanegold(I) dithiocarbamates,
several studies focussing on cytotoxicity profiles and mecha-
nisms of cell death have appeared [17–19]. Even more studies
of gold(III) dithiocarbamates are available as these potent
compounds exhibit in vivo potential, have limited nephrotox-
icity and a different mechanism of action to the widely used
anti-cancer drug cisplatin, (NH3)2PtCl2 [20–24]. Herein, we
redress this shortcoming in the gold/antimicrobial literature by
reporting the exciting antibacterial activity of 2–4, as outlined
above.
Experimental
Chemistry
The R3PAu[S2CN(iPr)CH2CH2OH] compounds, where R =
Ph (2), Cy (3) and Et (4), were prepared from the reaction of
t h e r e s p e c t i v e R 3 PAuC l p r e c u r s o r w i t h t h e
Na[S2CN(iPr)CH2CH2OH] salt as described in the literature
[19]. The compounds exhibited the reported spectroscopic
attributes (IR, 1H and 13C{1H} NMR). High-energy absorp-
tions (CHCl3 solution) ascribed to intraligand (IL) dithiocar-
bamate transitions [25] were noted in the UV–vis spectra run
on an Agilent Cary 60 UV–vis spectrophotometer, see Sup-
plementary Materials Table S1 for data. Photoluminescence
(PL) measurements were performed on an Agilent Varian
Cary Eclipse Fluorescence Spectrophotometer using a Xenon
flash lamp as the excitation source at room temperature, also
in CHCl3 solution; see Supplementary Materials Table S1 for
details. In the case of 3 and 4, the powder X-ray diffraction
patterns recorded on a PANalytical Empyrean XRD system
with Cu-Κα1 radiation (λ=1.54056 Å) in the 2θ range 5 to
40° with a step size of 0.026° were consistent with the simu-
lated patterns calculated using the single crystal data using
X’Pert HighScore Plus [26]; see Supplementary Materials
Fig. S1.
Antibacterial activity assay
The disk diffusion method was applied to screen for antibac-
terial activity in accordance with the Clinical and Laboratory
Standards Institute (CLSI) guidelines. A total of 25 bacterial
strains were included in this study, namely Aeromonas
hydrophilla ATCC 35654, Acinetobacter baumannii ATCC
19606, Bacillus cereus ATCC 10876, Bacillus subtilis ATCC
6633, Citrobacter freundii ATCC 8090, Enterobacter cloacae
ATCC 35030, Enterobacter aerogenes ATCC 13048, Entero-
coccus faecalis ATCC 29212, Enterococcus faecium ATCC
19434, Escherichia coliATCC 25922,Klebsiella pneumoniae
ATCC 700603, Listeria monocytogenes ATCC 19117, Prote-
us mirabilis ATCC 25933, Proteus vulgaris ATCC 13315,
Pseudomonas aeruginosa ATCC 27853, Salmonella
paratyphi A ATCC 9150, Salmonella typhimurium ATCC
Fig 1 Chemical structures of the trial gold compounds investigated
herein. Compound 2: R = Ph, 3: R = Cy and 4: R = Et. Compound 1 is
the sodium salt of dithiocarbamate anion
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14028, Shigella flexneri ATCC 12022, Shigella sonneiATCC
9290, S. aureus ATCC 25923, methicillin-resistant S. aureus
(MRSA) ATCC 43300, Staphylococcus saprophyticus ATCC
15305, Stenotrophomonas maltophilia ATCC 13637, Strepto-
coccus pyogenes ATCC 49399 and Vibrio parahaemolyticus
ATCC 17802. All bacterial cultures were purchased from
American Type Culture Collection (ATCC). The inoculum
suspension of each bacterial strain was adjusted to 0.5
McFarland standard turbidity (corresponding to approximate-
ly 108 CFU/ml) by adding Mueller-Hinton broth. This sus-
pension was then swabbed on the surface of Mueller-Hinton
agar (MHA) plates using a sterile cotton swab. The test
compounds were dissolved in DMSO to achieve a test con-
centration of 2 mg/ml. Sterile 6-mm filter paper discs were
aseptically placed on MHA surfaces and 5 μl of the dissolved
test compound was immediately added to the discs. Each plate
contained one standard antibiotic paper disc, serving as the
positive control, one disc served as negative control (5 μl
broth) and one disc served as solvent control (5 μl DMSO).
The plates were incubated at 37 °C for 24 h. Antibacterial
activity was evaluated bymeasuring the diameter of inhibition
zone against each bacterial strains. Each experiment was
performed in duplicate.
Determination of minimum inhibitory concentration
and minimum bactericidal concentration
A broth micro-dilution method was used to determine the
minimum inhibitory concentration (MIC) and minimum bac-
tericidal concentration (MBC) values according to the CLSI
guidelines. The test compounds were serially twofold diluted
in DMSO to achieve the range of test concentrations of 2,000–
0.06 μg/ml and then placed into each well of a 96-well
microplate. An inoculum suspension with density of
105 CFU/ml exponentially growing bacterial cells was added
into each well. The 96-well microplates were incubated at
Table 1 Antibacterial activity measured by zone of inhibition of 1–4 and standard antibiotics
Microorganism 1 2 3 4 Ciprofloxacin
(5 μg/disc)
Tetracycline
(30 μg/disc)
Chloramphenicol
(30 μg/disc)
Gram-Positive bacteria
B. cereus ATCC 10876 – 10 9 24 25 17 –
B. subtilis ATCC 6633 8 13 11 30 32 31 –
E. faecalis ATCC 29212 – 10 9 25 21 14 –
E. faecium ATCC 19434 – 9 9 24 14 – 22
L. monocytogenes ATCC 19117 8 12 10 26 21 27 –
S. aureus (MRSA) ATCC 43300 – 12 11 29 23 – 20
S. aureus ATCC 25923 8 10 9 27 23 – 18
S. saprophyticus ATCC 15305 – 12 10 32 23 30 –
S. pyogenes ATCC 49399 – 22 24 45 23 – 36
Gram-negative bacteria
A. baumannii ATCC 19606 – – – 15 22 20 –
A. hydrophilla ATCC 35654 – – – 13 26 27 –
C. freundii ATCC 8090 – – – 8 26 26 –
E. aerogenes ATCC 13048 – – – 11 25 22 –
E. cloacae ATCC 35030 – – – 9 28 22 –
E. coli ATCC 25922 – – – 11 29 24 –
K. pneumoniae ATCC 700603 – – – 8 28 15 –
P. aeruginosa ATCC 27853 – – – – 24 10 –
S. typhimurium ATCC 14028 – – – 11 31 22 –
S. paratyphi A ATCC 9150 – – – 10 33 27 –
S. flexneri ATCC 12022 – – – 14 31 26 –
S. sonnei ATCC 9290 – – – 10 31 26 –
S. maltophilia ATCC 13637 – – – 12 37 – 25
P. mirabilis ATCC 25933 – – – 12 37 – 19
P. vulgaris ATCC 13315 – – – 17 36 – 20
V. parahaemolyticus ATCC 17802 – – – 15 28 24 –
The diameter of inhibition zones in millimetres (mm) were measured around the disc after 24 h incubation; −, no zone of inhibition
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37 °C for 24 h. All tests were performed in triplicate. Four
controls comprisingmediumwith standard antibiotic (positive
control), mediumwith DMSO (solvent control), mediumwith
inoculum bacterial cells (negative control) and medium with
broth only (negative growth control) were included in each
test. Bacterial growth was detected by adding 50 μl of a
0.2 mg/ml p-iodonitrotetrazolium violet (INT) indicator solu-
tion into each of the microplate wells and incubated at 37 °C
for 30 min under aerobic agitation. Where bacterial growth
was inhibited, the suspension in the well remained clear after
incubation with INT. The INT will react in the presence of
bacterial activity, as indicated by a change from clear to a red
colour. The lowest concentration of the test compound which
completely inhibited bacterial growth was considered as the
MIC. AfterMIC determination, an aliquot of 100μl from each
well which showed no visible growth was spread onto MHA
and further incubated at 37 °C for 30 min. The MBC was
defined as the lowest concentration of the tested compound
Table 2 MIC (in microgram per millilitre) and MBC (in microgram per millilitre) of 1–4 and standard antibiotics against selected Gram-positive and
Gram-negative bacteria
Microorganism 1 2 3 4 Ciprofloxacin Tetracycline Chloramphenicol
MIC MBC/
MIC
MIC MBC/
MIC
MIC MBC/
MIC
MIC MBC/
MIC
MIC MBC/
MIC
MIC MBC/
MIC
MIC MBC/
MIC
Gram-Positive bacteria
B. cereus ATCC 10876 – – 15.63 1 31.25 1 0.98 1 3.91 1 125.00 1 – –
B. subtilis ATCC 6633 2000.00 1 15.63 1 62.50 1 0.98 1 0.98 1 1.95 1 – –
E. faecalis ATCC 29212 – – 62.50 2 125.00 1 1.95 32 15.63 1 250.00 1 – –
E. faecium ATCC 19434 – – 62.50 2 125.00 8 3.91 16 125.00 8 – – 250.00 ND
L. monocytogenes ATCC
19117
2000.00 1 31.25 1 62.50 1 1.95 2 15.63 1 250.00 1 – –
S. aureus (MRSA) ATCC
43300
– – 31.25 1 62.50 2 0.98 128 3.91 2 – – 250.00 1
S. aureus ATCC 25923 – – 31.25 2 125.00 1 1.95 64 7.81 1 – – 250.00 1
S. saprophyticus ATCC
15305
– – 31.25 1 125.00 1 1.95 1 7.81 2 7.81 ND – –
S. pyogenes ATCC 49399 500.00 1 7.81 2 31.25 1 1.95 1 15.63 1 – – 250.00 4
Gram-negative bacteria
A. baumannii ATCC
19606
– – – – – – 250.00 8 15.63 4 7.81 32 – –
A. hydrophilla ATCC
35654
– – – – – – 125.00 1 0.06 1 7.81 1 – –
C. freundii ATCC 8090 – – – – – – 1000.00 ND 0.12 1 15.63 32 – –
E. aerogenes ATCC
13048
– – – – – – 500.00 ND 0.49 32 31.25 32 – –
E. cloacae ATCC 35030 – – – – – – 1000.00 ND 0.12 4 31.25 ND – –
E. coli ATCC 25922 – – – – – – 15.63 125 0.24 2 7.81 ND – –
K. pneumoniae ATCC
700603
– – – – – – 1000.00 ND 7.81 1 250.00 ND – –
S. typhimurium ATCC
14028
– – – – – – 250.00 8 0.49 4 31.25 32 – –
S. paratyphi A ATCC
9150
– – – – – – 500.00 4 0.12 8 31.25 32 – –
S. flexneri ATCC 12022 – – – – – – 250.00 4 0.49 1 15.63 32 – –
S. sonnei ATCC 9290 – – – – – – 250.00 4 0.24 2 15.63 32 – –
S. maltophilia ATCC
13637
– – – – – – 125.00 16 1.95 64 – – 62.50 ND
P. mirabilis ATCC 25933 – – – – – – 250.00 2 0.98 8 – – 250.00 8
P. vulgaris ATCC 13315 – – – – – – 31.25 8 0.49 1 – – 250.00 4
V. parahaemolyticus
ATCC 17802
– – – – – – 125.00 1 1.95 1 1.95 1 – –
MIC minimum inhibitory concentration (μg/ml), MBC minimum bactericidal concentration (μg/ml), MBC/MIC ratio for bacteriostatic or bactericidal
activity, − not applicable; ND not determined as the bacterium had grown across all tested dilution (MBC >2000 μg/ml) which showed bacteriostatic
properties
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that produced a 99.9 % reduction in bacterial viable count on
the MHA.
Time-kill assay
Time-kill assays were performed by the broth macro-dilution
method in accordance with the CLSI guidelines. Inoculum
suspensions with approximately 105 CFU/ml of exponentially
growing bacterial cells were used in this study. The test
compound was added to 10 ml of inoculum suspensions with
final concentrations corresponding to ½x MIC, MIC and 2x
MIC. A growth control comprising the bacterial strain without
the test compound was included in each trial. The inoculum
cultures were incubated at 37 °C on an orbital shaker at
200 rpm. Aliquots were removed from the inoculum culture
after timed intervals of incubation (i.e. 0, 1, 2, 3 and 4 h, and 0,
4, 8 and 24 h), and serial tenfold dilutions were prepared in
saline as needed. The numbers of viable cells were determined
by the plate count technique which involved plating 25 μl of
each dilution on a MHA plate [27]. All plates were incubated
Fig 2 Time-kill curves of 2 against a B. cereus, b B. subtilis, c E. faecalis, d E. faecium, e L. monocytogenes, f S. aureus (MRSA), g S. aureus, h
S. saprophyticus and i S. pyogenes. The bactericidal level is indicated by the dashed lines , growth control , 2x MIC , MIC and ½x MIC
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at 37 °C for 24 h. The experiments were performed in tripli-
cate. Data were analysed as killing curves by plotting the log10
colony forming unit per millilitre (cfu/ml) versus time (hours),
and the change in bacterial concentration was determined. The
viable bacterial cell count for the time-kill end point determi-
nation, i.e. bactericidal activity, is defined as a reduction of ≥3
log10 cfu/ml relative to the initial inoculum, whereas bacteri-
ostatic activity corresponds to <3 log10 cfu/ml decrease rela-
tive to the initial inoculum [28].
Results and discussion
Chemistry
The R3PAu[S2CN(iPr)CH2CH2OH] compounds, where R =
Ph (2), Cy (3) and Et (4), and sodium dithiocarbamate salt (1),
became available in an earlier study describing their cytotox-
icity against MCF-7R breast cancer cells and their differing
pathways of causing cell death, i.e. apoptopic for 2 and
Fig 3 Time-kill curves of 3 against a B. cereus, b B. subtilis, c E. faecalis, d E. faecium, e L. monocytogenes, f S. aureus (MRSA) and g S. pyogenes. The
bactericidal level is indicated by the dashed lines , growth control , 2x MIC , MIC and ½x MIC
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necrotic for 3 and 4 [19]; the salt was non-cytotoxic. The
motivation for the present study arose from recent observa-
tions of remarkable antimicrobial activities, specifically
against Gram-positive bacteria, exhibited by related
phosphanegold(I) thiocarbamate compounds, i .e.
Ph3PAu[SC(OR)=N(tol-p)], for R = Me, Et and iPr [29], and
by the knowledge that other metal dithiocarbamates have been
reported to exhibit antimicrobial activity [30–32].
Crystal structure analysis on 3 and 4 [19] proved linear P–
Au–S coordination geometries with the second sulphur atom
oriented towards gold as indicated in Fig. 1. While the struc-
ture of 2 remains unverified, literature precedents suggest a
similar coordination arrangement [33, 34]. 1H NMR spectra
run in DMSO solution after 24 h were unchanged compared
with freshly prepared solutions proving the stability of 2–4 in
the time-frame of the biological studies. The gold compounds
are insoluble in water.
Anti-bacterial activity
The antibacterial properties of 2–4 along with the dithiocar-
bamate salt 1 were evaluated against both Gram-positive and
Gram-negative bacteria using the Kirby-Bauer disk diffusion
method. According to the results collected in Table 1, 2–4
were specifically effective against all tested Gram-positive
bacteria but against not Gram-negative bacteria. By contrast,
4 was the most active compound with significant inhibitory
activity towards all the tested Gram-positive and Gram-
negative pathogens except P. aeruginosa. This finding indi-
cates that 2 and 3 has a similar inhibitory mechanism of action
towards Gram-positive bacteria only, whereas 4 possesses
wider spectrum of inhibitory activity against both Gram-
positive and Gram-negative bacteria that is similar to that
exhibited by the standard antibiotic ciprofloxacin.
The antibacterial activity of 1–4 were quantitatively
assessed by determining their minimum inhibitory concentra-
tion (MIC) values and the results are tabulated in Table 2; a
lower MIC value indicates a better antimicrobial agent as less
compound is required to inhibit growth of the bacteria. The
MIC values of compounds 2–4 were in the range 0.98–
2,000.00μg/ml, whereas ciprofloxacin was active in the range
of 0.06–125.00 μg/ml, tetracycline in the range of 1.95–
250.00 μg/ml and chloramphenicol in the range of 62.50–
250.00 μg/ml towards susceptible tested bacteria. Salt 1 ex-
hibited low activity and only shows inhibition against
B. subtilis, L. monocytogenes and S. pyogenes, with high
MIC values of 2,000.00, 2,000.00 and 500.00 μg/ml, respec-
tively. This result points to the importance of phosphine gold
in imparting antibacterial activity.
Compounds 2 and 3were effective in inhibiting the growth
of all tested Gram-positive bacteria with MIC values in the
range of 7.81–62.5 and 31.25–125.00 μg/ml, respectively. As
shown in Table 2, the antibiotic ciprofloxacin used as standard
drug was more potent than the tested compounds 2 and 3
against Gram-positive bacteria at low concentration (MIC=
0.98–125.00 μg/ml) with the exception against S. pyogenes
where it was less active compared with 2. However, standard
drugs tetracycline and chloramphenicol were less potent than
2 and 3 against Gram-positive bacteria at higher concentration
(MIC=125.00–250.00 μg/ml) with exception against
B. subtilis and S. saprophyticus. Interestingly, 4 displayed
excellent inhibitory activity towards Gram-positive bacteria,
with lower MIC values in the range 0.98–3.91 μg/ml, com-
pared with 2 and 3, and the standard drugs ciprofloxacin,
tetracycline and chloramphenicol,. In addition, 4, with MIC
values in the range of 15.63–1,000.00 μg/ml, also showed
moderate antibacterial activity against Gram-negative bacte-
ria. The standard drugs ciprofloxacin, tetracycline and chlor-
amphenicol showed remarkable high activity against Gram-
negative bacteria (MIC=0.06–250.00 μg/ml) compared with
4 with the exception of chloramphenicol against P. vulgaris.
The most susceptible strains towards 4 were methicillin
resistant S. aureus (hereafter, MRSA) and Bacillus spp.
(MIC=0.98 μg/ml), followed by Staphylococcus spp.
(MIC=1.95 μg/ml), L. monocytogenes (MIC=1.95 μg/ml),
S. pyogenes (MIC=1.95 μg/ml) and Enterococcus spp.
(MIC=1.95-3.91 μg/ml). These observations suggest poten-
tial efficacy for treatment against a variety of ailments as the
susceptible bacterial strains typically cause disease in humans.
For example, Staphylococcus spp., Enterococcus spp. and
Bacillus spp. cause urinary tract infection, nosocomial infec-
tion and bacteraemia [35–37], L. monocytogenes causes liste-
riosis and meningitis [38] and S. pyogenes causes bacteraemia
and meningitis [39]. Furthermore, the MIC values obtained
for 4 were relatively lower than the MIC values for the
aforementioned Ph3PAu[SC(OR)=N(tol-p)], for R = Me, Et
and iPr [29], series of compounds against B. cereus (MIC=1–
4 μg/ml), S. aureus (MIC=37 μg/ml), E. faecalis (MIC=
4 μg/ml) and E. faecium (MIC=37 μg/ml), and gold
sulfanylcarboxylates [10] against S. aureus (MIC=6.25–
200.00 μg/ml) and B. subtilis (MIC=6.25–200.00 μg/ml). In
summary, the data indicates that 4, with its high antibacterial
activity, could be further developed as an antimicrobial agent
towards MRSA, Staphylococcus spp., Bacillus spp. and
Enterococcus spp.
The bactericidal properties of 2–4 against susceptible
strains (i.e. excluding P. aeruginosa) were analysed by the
minimum bactericidal concentration (MBC) assay and sum-
marized as MBC/MIC ratios in Table 2. An antimicrobial
agent is considered bactericidal if the MBC is not more than
Fig 4 Time-kill curves of 4 against aB. cereus, bB. subtilis, cE. faecalis,
d E. faecium, e L. monocytogenes, f S. aureus (MRSA), g S. aureus, h
S. saprophyticus, i S. pyogenes, j E. coli and k P. vulgaris. The
bactericidal level is indicated by the dashed lines , growth control
, 2x MIC , MIC and ½x MIC
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fourfold higher than the MIC, i.e. MBC/MIC≤4 [40]. Com-
pounds 1–3 were shown to be bactericidal (MBC/MIC≤2)
towards the susceptible Gram-positive strains with exception
of 3, against E. faecium, with the MBC being eightfold higher
than the MIC indicating bacteriostatic character. For 4, bacte-
ricidal activity was observed positive against B. cereus,
B. subtilis, L. monocytogenes, S. saprophyticus, S. pyogenes,
A. hydrophilla, S. paratyphi A, S. flexneri, S. Sonnei,
P. mirabilis and V. parahaemolyticus, whereas bacteriostatic
activity on E. faecalis, E. faecium, MRSA, S. aureus,
A. baumannii, C. freundii, E. aerogenes, E. cloacae, E. coli,
K. pneumonia, S. typhimurium, S. maltophilia and P. vulgaris
was indicated. These results suggest that the bacteriostatic and
bactericidal activities of 2–4 are dependent on the bacterial
strain. This behaviour is similar to standard antibiotic cipro-
floxacin, which is classified primarily as a bactericidal drug,
so that the MBC/MIC≤4 might have been predicted. Cipro-
floxacin has been shown to kill bacteria by binding their DNA
Gyrase subunit which causes inhibition of bacteria DNA
replication [41]. However, the MBC values of ciprofloxacin
towards E. faecium (MBC/MIC=8), E. aerogenes (32),
S. paratyphi A (8), S. maltophilia (64) and P. mirabilis (8)
were fourfold, or more, higher than the MIC indicating bac-
teriostatic activity. The present findings confirm the conclu-
sions of earlier studies [42, 43], where it was shown that the
antibacterial agent vancomycin is generally bactericidal
against S. aureus and pneumococci, but bacteriostatic against
enterococci.
Time-kill assays have been widely used for in vitro inves-
tigations of new antimicrobial agents as these provide descrip-
tive (qualitative) information on the pharmacodynamics of
antimicrobial agents [44]. In the present study, only gold
compounds with high activity towards susceptible bacteria
strains, i.e. with MIC<100 μg/ml, were selected for time-kill
studies. The kinetic interaction between susceptible bacteria
and 2–4 were examined at concentrations of two times the
MIC (2x MIC), MIC and one-half of the MIC (½x MIC).
The kill kinetic profiles of 2 and 3 (Figs. 2 and 3) displayed
rapid bactericidal activity towards all susceptible strains,
showing a ≥3log10 reduction in viable cell count relative to
the initial inoculum at all tested concentrations after 1 h
exposure (Table 3). As expected from the determined MBC/
MIC ratios, the time-kill assays for 2 towards B. cereus,
B. subtilis, E. faecalis, E. faecium, L. monocytogenes, MRSA,
S. aureus, S. saprophyticus and S. pyogenes were consistent
with bactericidal characteristic. A similar conclusion is appar-
ent for 3 towards B. cereus, B. subtilis, L. monocytogenes,
MRSA and S. pyogenes.
The kill kinetic profiles of 4, shown in Fig. 4, exhibited
varying degrees of bactericidal and bacteriostatic activities
depending on the tested strains and concentrations. After 1 h
and at all concentrations tested, Table 3, 4 had a similar killing
rate as 2 and 3 against B. cereus, B. subtilis and S. pyogenes.
The killing rate of 4 was slower than 2 and 3 against
E. faecalis, E. faecium, L. monocytogenes and MRSA in
which bactericidal activities were only seen after 3 h interac-
tion at 2x MIC. Compared to 2, 4 exhibited a slower killing
rate against S. aureus and S. saprophyticus, showing bacteri-
cidal activity only after 3 h (2x MIC) and 4 h (½x MIC),
respectively. In summary and consistent with the MBC/MIC
ratios (Table 2), at its MIC value, 4 was found to be bacteri-
cidal towards B. cereus, B. subtilis, L. monocytogenes,
S. saprophyticus and S. pyogenes after 24 h exposure. On
the other hand, at its MIC value 4 is bacteriostatic towards
E. faecalis, E. faecium, MRSA and S. aureus, as well as the
Gram-negative bacteria E. coli and P. vulgaris.
Aggressive bactericidal activities for 4 can be achieved at
concentrations higher than MIC, e.g. 2x MIC, over 24 h with
E. faecalis, E. faecium, MRSA, S. aureus and E. coli. At its
MIC value, 4 showed bacteriostatic activity against P. vulgaris
(Fig. 4k) after 4 h contact but the strain regrew to the same
level as the control inoculum after 24 h. Similarly, regrowth
occurred in E. coli after 4 h of exposure to 4 at MIC and ½x
MIC. This regrowth incidence was not found with the other
strains tested, but is common in studies of bacterial killing rate
with antimicrobial agents in time-kill assays [45]. The re-
growth phenomenon was attributed to two distinct sub-
populations with different susceptibility in which the selective
growing of resistant sub-population take over the preferential
killing of the susceptible sub-population at a specified time of
interaction [44].
In order to place the time-kill assays determined for 2–4 in
context, some observations from the literature are made.
Vidaillac et al. [46] demonstrated that oritavancin exhibited
rapid bactericidal activity against MRSA after 9 h exposure. In
the present study, the kill kinetic profiles of 2 and 3 displayed
much more rapid bactericidal activity, i.e. within 1 h, toward
MRSA and other susceptible pathogens compared to
oritavancin. Furthermore, the kill kinetic profiles of 4 exhib-
ited both bactericidal and bacteriostatic activities depending
on the tested strains and concentrations. The behaviour is
similar to that exhibited by various oxazolidinone derivatives
which demonstrated bacteriostatic effects toward
Staphylococcus spp. and Enterococcus spp. but a bactericidal
effect toward Streptococcus spp. [47].
In conclusion, three active gold compounds possess potent
and differential activity against Gram-positive and Gram-
negative bacteria pathogens, including the MRSA strain,
which is often multi-resistant to several classes of antibiotics
and can cause severe hospital-acquired and community-
acquired infections. With rapid bactericidal activity against
Gram-positive bacteria, 2 and 3 could provide clinical benefits
over bacteriostatic therapy in neutropenia by rapid elimination
of a bacterial pathogen and thereby reduce the likelihood of
the spread of infection.With lowMIC values, 4 could serve as
a potential broad-spectrum antibacterial agent against Gram-
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positive and Gram-negative bacterial infections. The time-kill
studies have provided valuable information on the rate, con-
centration and potential action of antibacterial agents in vitro.
As the antibacterial activities and bacterial killing rates of 2–4
were different from each other, it is likely that different mech-
anisms are involved. Further investigation is needed to deter-
mine the mechanism(s) of action of these compounds in order
to strengthen their potential as therapeutic antibiotics. Further
derivatives, i.e. by varying both phosphane- and
dithiocarbamate-substituents, will also be developed in a
structure-activity study. In particular, of the present series, 4,
with its potent and specific antibacterial profile, is deserving
of further investigation and in vivo studies are planned.
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